Justin Bowers
Stock Analyst at Deutsche Bank
(2.02)
# 3,287
Out of 4,983 analysts
129
Total ratings
47.6%
Success rate
0.4%
Average return
Main Sectors:
Stocks Rated by Justin Bowers
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CON Concentra Group Holdings Parent | Rated: Buy | $32 → $41 | $35.53 | +15.40% | 3 | Aug 10, 2026 | |
| CRL Charles River Laboratories International | Reiterated: Buy | $185 → $300 | $281.67 | +6.51% | 12 | Aug 6, 2026 | |
| WAT Waters | Rated: Hold | $350 → $400 | $429.72 | -6.92% | 11 | Aug 5, 2026 | |
| AVTR Avantor | Reiterated: Hold | $25 → $13 | $15.86 | -18.03% | 7 | Jul 30, 2026 | |
| FTRE Fortrea Holdings | Reiterated: Hold | $14 → $20 | $20.28 | -1.38% | 7 | Jul 30, 2026 | |
| MEDP Medpace Holdings | Reiterated: Hold | $430 → $535 | $615.18 | -13.03% | 4 | Jul 23, 2026 | |
| DHR Danaher | Rated: Buy | $270 → $240 | $212.50 | +12.94% | 11 | Jul 22, 2026 | |
| TMO Thermo Fisher Scientific | Reiterated: Buy | $620 → $630 | $658.32 | -4.30% | 10 | Jul 9, 2026 | |
| TECH Bio-Techne | Downgraded: Hold | $66 → $73 | $72.41 | +0.81% | 9 | Jun 26, 2026 | |
| ICLR ICON Public Limited Company | Reiterated: Buy | $370 → $188 | $169.68 | +10.80% | 8 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $6 | $7.27 | -17.47% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 → $23 | $76.97 | -70.12% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $345 → $315 | $366.60 | -14.08% | 6 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $260 → $220 | $269.44 | n/a | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $155 → $175 | $178.19 | n/a | 8 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $70 | $123.14 | n/a | 1 | Sep 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $245.18 | n/a | 1 | Jan 17, 2014 |
Concentra Group Holdings Parent
Aug 10, 2026
Rated: Buy
Price Target: $32 → $41
Current: $35.53
Upside: +15.40%
Charles River Laboratories International
Aug 6, 2026
Reiterated: Buy
Price Target: $185 → $300
Current: $281.67
Upside: +6.51%
Waters
Aug 5, 2026
Rated: Hold
Price Target: $350 → $400
Current: $429.72
Upside: -6.92%
Avantor
Jul 30, 2026
Reiterated: Hold
Price Target: $25 → $13
Current: $15.86
Upside: -18.03%
Fortrea Holdings
Jul 30, 2026
Reiterated: Hold
Price Target: $14 → $20
Current: $20.28
Upside: -1.38%
Medpace Holdings
Jul 23, 2026
Reiterated: Hold
Price Target: $430 → $535
Current: $615.18
Upside: -13.03%
Danaher
Jul 22, 2026
Rated: Buy
Price Target: $270 → $240
Current: $212.50
Upside: +12.94%
Thermo Fisher Scientific
Jul 9, 2026
Reiterated: Buy
Price Target: $620 → $630
Current: $658.32
Upside: -4.30%
Bio-Techne
Jun 26, 2026
Downgraded: Hold
Price Target: $66 → $73
Current: $72.41
Upside: +0.81%
ICON Public Limited Company
Jun 25, 2026
Reiterated: Buy
Price Target: $370 → $188
Current: $169.68
Upside: +10.80%
May 8, 2026
Reiterated: Buy
Price Target: $10 → $6
Current: $7.27
Upside: -17.47%
May 8, 2026
Reiterated: Hold
Price Target: $17 → $23
Current: $76.97
Upside: -70.12%
Feb 13, 2026
Reiterated: Buy
Price Target: $345 → $315
Current: $366.60
Upside: -14.08%
Jul 29, 2025
Reiterated: Buy
Price Target: $260 → $220
Current: $269.44
Upside: n/a
Aug 16, 2024
Reiterated: Buy
Price Target: $155 → $175
Current: $178.19
Upside: n/a
Sep 16, 2019
Initiated Coverage: Hold
Price Target: $70
Current: $123.14
Upside: n/a
Jan 17, 2014
Reiterated: Buy
Price Target: $140
Current: $245.18
Upside: n/a